Form 4: Ocular Therapeutix CLO Sells Shares for Tax Obligations

Ocular Therapeutix's Chief Legal Officer, Todd Anderman, sold 11,132 shares of common stock at a weighted average price of $12.34 to cover tax withholding obligations related to RSU vesting.

Summary

• Todd Anderman, Chief Legal Officer of Ocular Therapeutix, Inc. (OCUL), reported a sale of common stock.
• On October 8, 2025, 11,132 shares of common stock were sold.
• The sale was executed at a weighted average price of $12.34 per share, with prices ranging from $12.00 to $12.5114.
• This transaction was a pre-planned "sell-to-cover" to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs) on October 7, 2025.
• The sale was made pursuant to a durable automatic sale instruction adopted on October 7, 2024, and does not represent a discretionary trade.
• Following the transaction, Todd Anderman beneficially owns 87,568 shares of Ocular Therapeutix common stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell-to-cover' for tax obligations, which is neutral in terms of company performance or insider sentiment. It neither indicates strong positive nor negative developments.

Positives

• The transaction was non-discretionary and pre-planned, indicating no new negative sentiment from the insider.
• The sale was for tax obligations, a common and expected event for RSU vesting.

Negatives

• A reduction in insider ownership, albeit for tax purposes, could be perceived negatively by some investors.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Management Comments

• Represents shares of common stock of Ocular Therapeutix, Inc. (the 'Corporation') sold, pursuant to a durable automatic sale instruction adopted by the reporting person on October 7, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on October 7, 2025.
• The sales do not represent a discretionary trade by the reporting person.

Industry Context

This is a routine insider transaction for tax purposes and does not provide broader industry context or specific insights into Ocular Therapeutix's operational performance or market position within the biotechnology or pharmaceutical industry.

Comparison to Industry Standards

• This type of 'sell-to-cover' transaction for tax obligations upon RSU vesting is a standard practice for executives across all industries, including biotechnology, and is not indicative of unique company-specific or industry-specific performance issues. It aligns with common compensation and tax planning strategies for equity awards.

Corporate Governance

Related Party Transactions

• The sale of common stock by Todd Anderman, an officer of Ocular Therapeutix, Inc., constitutes an insider transaction.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but for a routine tax purpose, so minimal impact on investor confidence.
• Company: Ensures compliance with tax obligations for an executive's equity compensation.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary 'sell-to-cover' transaction by a Chief Legal Officer to satisfy tax obligations upon RSU vesting. Such transactions are common and do not typically reflect a change in the insider's view of the company's prospects or fundamental performance. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is maintained based solely on this filing.

Keywords

Ocular Therapeutix, OCUL, Todd Anderman, Chief Legal Officer, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Sell-to-Cover, Beneficial Ownership